UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

 

FORM 8-K
CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

_______________________

Date of Report: February 11, 2016 (Date of earliest event reported)

 

 

  CAPSTONE THERAPEUTICS CORP.  

 (Exact name of registrant as specified in its charter)

 

Delaware   000-21214   86-0585310
(State or other jurisdiction of
incorporation)		   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

 

1275 West Washington Street, Suite 104, Tempe, Arizona   85281
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:
(602) 286-5520

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[   ]     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[   ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[   ]     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[   ]     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Section 2—Financial Information

 

Item 2.02Results of Operations and Financial Condition.

 

A copy of the presentation for the conference call, referenced in the press release issued by Capstone Therapeutics Corp. on February 3, 2016, is furnished as Exhibit 99.1 to this Current Report on Form 8-K, entitled “Capstone Therapeutics Corp. Operating Update, February 11, 2016”. The presentation will also be accessible during the conference call by logging onto the Investors section of the Company’s website, www.capstonethx.com.

 

The information in Item 2.02 of this Form 8-K and Exhibit 99.1 furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filing.

 

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01   Financial Statements and Exhibits.
     
(d)   Exhibits
     
Exhibit No.   Description
     
99.1   Capstone Therapeutics Corp. Operating Update, February 11, 2016

 

 

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  Dated:  February 11, 2016 CAPSTONE THERAPEUTICS CORP.
       
       
    /s/ John M. Holliman, III  
    John M. Holliman, III  
    Executive Chairman